Colorado Therapeutics earns FDA nod for biologic soft tissue repair implant


The FDA cleared Colorado Therapeutics’ xenograft implant for the surgical repair of damaged soft tissue membranes, including hernias. The company is now planning a financing round and prepping for a U.S. commercial launch.

The xenograft implant is designed to strengthen soft tissue where it is weak and for the surgical repair of damaged or ruptured membranes, according to a statement. The xenogenic biologic tissue matrix is derived from different mammalian species and can be stored dry, so it is ready for use straight off the shelf, the company said. The biocompatible tissue has “superior benefits” over existing biologic or synthetic products.

Colorado Therapeutics will open a Series A round to help it round up the funds it needs to drive the implant’s commercial launch. The company will also put the proceeds toward advancing its pipeline products based on its tissue-processing tech, according to the statement.


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

Its pipeline products include xenogenic tendons for tendon or ligament repair or replacement, implants for abdominal wall reconstruction and xenogenic veins for use in vascular repair or to create fistulas for dialysis.

“The receipt of this 510(k) clearance is a significant milestone for Colorado Therapeutics and will be a spring board for advancing the Company’s product pipeline, which includes other soft tissue repair opportunities such as dura repair, skin substitutes, covered stents for peripheral vascular disease, and vascular grafts,” said CEO Joseph Horn.


Suggested Articles

Weeks after receiving FDA approval for its in-office eardrum tube device, Tusker Medical has been picked up by Smith & Nephew for an undisclosed sum.

As public fascination with at-home DNA tests begins to wane, 23andMe announced that it will lay off about 100 of its staff, according to CNBC.

The Rady Children’s Institute for Genomic Medicine tapped Deloitte to help develop a network of flying drones to deliver genetic testing specimens.